Rodman & Renshaw Initiates Coverage of Arena Pharmaceuticals (ARNA) with a Market Outperform
ARNA Hot Sheet
Rating Summary:4 Buy, 7 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Rodman & Renshaw initiates coverage of Arena Pharmaceuticals (Nasdaq: ARNA) with a Market
Outperform rating Price target $9.
Rodman analyst says, "We view the company's obesity drug, lorcaserin, as promising relative to marketed and development-stage obesity drugs."
To see more analyst ratings on ARNA Click Here.
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
Outperform rating Price target $9.
Rodman analyst says, "We view the company's obesity drug, lorcaserin, as promising relative to marketed and development-stage obesity drugs."
To see more analyst ratings on ARNA Click Here.
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Credit Suisse Starts Carrizo Oil & Gas (CRZO) at Neutral
- Stocks with implied volatility below IV index mean; HLF ARNA
Create E-mail Alert Related Categories
New CoverageRelated Entities
Rodman & RenshawSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
